Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT-Reference-Cited by-同舟云学术

Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT

Published:2023-01-21 Issue:4 Volume:58 Page:424-429
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Waszczuk-Gajda Anna,Gras Luuk,de Wreede Liesbeth C.^ORCID,Sirait Tiarlan,Illes Arpad,Ozkurt Zubeyde Nur,Snowden John A.^ORCID,Arat Mutlu^ORCID,Bulabois Claude Eric,Niederland Judith,Sever Matjaz,Paneesha Shankara,Potter Victoria,Gadisseur Alain,Chalopin Thomas,Van Gorkom Gwendolyn,López Joaquin Martínez,Kerre Tessa,Drozd-Sokolowska Joanna^ORCID,Raj Kavita^ORCID,Hayden Patrick J.^ORCID,Beksac Meral,Yakoub-Agha Ibrahim^ORCID,McLornan Donal P.^ORCID,Schönland Stefan^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-01915-7.pdf

Reference22 articles.

1. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N. Engl J Med. 2017;376:1311–20. https://doi.org/10.1056/NEJMoa1611750

2. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1617–29. https://doi.org/10.1016/S1470-2045(15)00389-7.

3. Cavo M, Gay F, Beksac M, Dimopoulos MA, Pantani L, Petrucci MT, et al. Upfront autologous hematopoietic stem-cell transplantation improves overall survival in comparison with bortezomib-based intensification therapy in newly diagnosed multiple myeloma: long-term follow-up analysis of the randomized Phase 3 EMN02/HO95 Study. Blood. 2020;1361:37–38. https://doi.org/10.1182/blood-2020-137575

4. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl J Med. 2022;387:132–47. https://doi.org/10.1056/NEJMoa2204925.

5. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114:822–9. https://doi.org/10.1046/j.1365-2141.2001.03033.x

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era;Clinical and Experimental Medicine;2024-09-09

2. Autologous stem cell transplantation in newly diagnosed multiple myeloma patients with severe renal failure requiring hemodialysis. A single-center experience;Oncohematology;2024-09-02

3. Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?;Hematology/Oncology Clinics of North America;2023-12

4. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care;Annals of Hematology;2023-10-25